title: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
abstract: AbbVie's 3 direct-acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir, and dasabuvir with and without ribavirin is approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Safe and efficacious antiviral regimens resulting in minimal to no drug-drug interactions (DDIs) with antiretrovirals are needed to ensure that patients coinfected with HCV and the human immunodeficiency virus (HIV) achieve 12-week sustained virologic response rates similar to HCV-monoinfected patients. Also, the prevalence of injection drug use history is high in both monoinfected and HIV/HCV-coinfected patients. This review summarizes results from phase 1 DDI studies of the 3D regimen and antiretrovirals or drugs to treat substance abuse. Data suggest the 3D regimen is a viable option for HIV/HCV-coinfected patients on antiretroviral therapy containing tenofovir/emtricitabine, abacavir/lamivudine, dolutegravir, raltegravir, or atazanavir. HCV-infected patients receiving medications for substance abuse, particularly methadone or buprenorphine/naloxone, can also be treated with the 3D regimen.
authors.affiliation: AbbVie, Clinical Pharmacology and Pharmacometrics, North Chicago, IL, USA.
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: King
authors.affiliation: AbbVie, Clinical Pharmacology and Pharmacometrics, North Chicago, IL, USA.
authors.forename: Rajeev M
authors.initials: RM
authors.lastname: Menon
mesh_terms: D015081:2-Naphthylamine; D000813:Anilides / Q000493:pharmacokinetics / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002219:Carbamates / Q000493:pharmacokinetics / Q000627:therapeutic use; D060085:Coinfection / Q000188:drug therapy* / Q000378:metabolism; D003521:Cyclopropanes; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D006526:Hepatitis C / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use; D011392:Proline / Q000031:analogs & derivatives; D011480:Protease Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D019438:Ritonavir / Q000493:pharmacokinetics / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000378:metabolism; D013449:Sulfonamides / Q000493:pharmacokinetics / Q000627:therapeutic use; D014498:Uracil / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D014633:Valine
chemical_list: D000813:Anilides; D044966:Anti-Retroviral Agents; D002219:Carbamates; D003521:Cyclopropanes; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds; D011480:Protease Inhibitors; D013449:Sulfonamides; C586094:ombitasvir; D014498:Uracil; D011392:Proline; D015081:2-Naphthylamine; C588260:dasabuvir; D014633:Valine; D019438:Ritonavir; C585405:paritaprevir
keywords: Human Immunodeficiency Virus; antiretrovirals; buprenorphine; hepatitis C virus; methadone; pharmacokinetics